Effects of Recombinant Human Brain Natriuretic Peptide on brain natriuretic peptide level and cardiac function in patients with acute myocardial infarction after percutaneous coronary intervention
XING Dong LIAO Peichao MA Zhiqiang
Department of Cardiology, Tengzhou Hospital of Traditional Chinese Medicine
Abstract: Objective To investigate the effect of Recombinant Human Brain Natriuretic Peptide in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods A total of 84 AMI patients admitted to Tengzhou Hospital of Traditional Chinese Medicine from July 2018 to December 2020 were selected and divided into control group and observation group by random number table method, with 42 cases in each group. The control group was given conventional drug therapy after PCI, and the observation group was treated with Recombinant Human Brain Natriuretic Peptide, both groups were followed up for 6 months after treatment. Clinical efficacy, cardiac function,brain natriuretic peptide (BNP) level and incidence of adverse events were compared between the two groups. Results The total effective rate of clinical treatment and left ventricular ejection fraction (LVEF) in the observation group were higher than those in the control group, BNP level, total incidence of adverse events were lower than those in the control group, left ventricular diastolic diameter (LVEDD) and left ventricular posterior wall thickness (LVPWT) were less than those in the control group, the differences were statistically significant (P<0.05). Conclusion The application of Recombinant Human Brain Natriuretic Peptide in AMI patients after PCI can improve the cardiac function, reduce the level of BNP and the incidence of adverse events, which is conducive to the prognosis of patients.
邢栋;廖培超;马志强. 重组人脑利钠肽对急性心肌梗死患者经皮冠状动脉介入术后脑钠肽水平及心功能的影响[J]. 中国当代医药, 2022, 29(16): 100-102.
XING Dong;LIAO Peichao;MA Zhiqiang. Effects of Recombinant Human Brain Natriuretic Peptide on brain natriuretic peptide level and cardiac function in patients with acute myocardial infarction after percutaneous coronary intervention. 中国当代医药, 2022, 29(16): 100-102.